1-2 of 2
Anthony M. Neuger
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with Autologous Stem Cell Transplant in Refractory Cancer: Pharmacokinetic and Pharmacodynamic Correlates

Janelle B. Perkins, Steven C. Goldstein, Jana L. Dawson, Jongphil Kim, Teresa L. Field, James S. Partyka, Karen K. Fields, Beth L. Maddox, Christine E. Simonelli, Anthony M. Neuger, Richard M. Lush, Daniel M. Sullivan
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (24): 7743–7753.
https://doi.org/10.1158/1078-0432.CCR-11-1540
Published: 18 December 2011
View article titled, Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with Autologous Stem Cell Transplant in Refractory Cancer: Pharmacokinetic and Pharmacodynamic Correlates
Open the PDF for Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with Autologous Stem Cell Transplant in Refractory Cancer: Pharmacokinetic and Pharmacodynamic Correlates in another window
Includes: Supplementary data
Journal Articles

Phase I/II Study of Atrasentan, an Endothelin A Receptor Antagonist, in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Advanced Non–Small Cell Lung Cancer

Alberto A. Chiappori, Eric Haura, Francisco A. Rodriguez, David Boulware, Rachna Kapoor, Anthony M. Neuger, Richard Lush, Barbara Padilla, Michelle Burton, Charles Williams, George Simon, Scott Antonia, Daniel M. Sullivan, Gerold Bepler
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (5): 1464–1469.
https://doi.org/10.1158/1078-0432.CCR-07-1508
Published: 03 March 2008
View article titled, Phase I/II Study of Atrasentan, an Endothelin A Receptor Antagonist, in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Advanced Non–Small Cell Lung Cancer
Open the PDF for Phase I/II Study of Atrasentan, an Endothelin A Receptor Antagonist, in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Advanced Non–Small Cell Lung Cancer in another window